Drug Clinical Trials List

Display 651 - 660 from 730

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
Superiority of Insulin Glargine Lantus vs. NPH: Treat to Normoglycemia Concept.Effect of Insulin Glargine in Comparison to Insulin NPH in Insulin-nave People With Type 2 Diabetes Mellitus Treated With at Least One OAD and Not Adequately Controlled	Sanofi	Ongoing	Lantus®	4	Lantu_C_02762	King Abdulaziz University Hospital (Jeddah), King Fahad University Hospital (Al-Khobar)
Registry in the management of Acute Diarrhea in Children : Observational study in Daily practice	Sanofi	Ongoing	N/A	4	DIREG_R_06373	King Fahad Medical City (Riyadh)
Unmet needs in allergic rhinitis: International Survey on Mangment of Allergic Rhinitis by Physician and Patient.	Sanofi	Ongoing	N/A	4	DIREG_R_06411	Soliman Fakeeh Hospital (Jeddah)
International Diabetes Management Practice Study - IDMPS	Sanofi	Ongoing	N/A	4	DIREG_R_05168	King Fahad Hospital (Jeddah)
Venous Thromboembolic Risk Assessment of Post-Partum Females in Saudi Arabia Utilizing Royal College of Obstetrics and Gynecology Risk Assessment Model	Sanofi	Ongoing	N/A	4	DIREG_L_06410	King Abdulaziz University Hospital (Jeddah)
The Influence of a rapid relief of gastro esophageal reflux disease (GERD) symptoms on the quality of life and patient satisfaction after initiating treatment with a Proton Pump Inhibitor.	Sanofi	Ongoing	N/A	4	DRIEG_L_05705	University District Hospital (Jeddah)
An observational registry improving Control of Hypertension and Achieving Normalization Goal Earlier	Sanofi	Ongoing	N/A	4	DIREG_L_05059	Erfan & Bagedo General Hospital (Jeddah)
An observational study to monitor the efficacy and tolerability of levofloxacin 250 mg OD for treatment of simple lower UTI in Saudi Arabia	Sanofi	Ongoing	Levofloxacin	4	LEVOF_L_05172	Erfan & Bagedo General Hospital (Jeddah)
International Diabetes Management Practices Study (Wave 5)	Sanofi	Ongoing	N/A	4	DIREG_R_05941	King Fahad Hospital (Jeddah)
A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP).	Bayer	Completed	Riociguat	2	BAY 63-2521 / 13605	King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh)